Depletion of hsa_circ_0000144 Suppresses Oxaliplatin Resistance of Gastric Cancer Cells by Regulating miR-502-5p/ADAM9 Axis
Circular RNAs (circRNAs) have been disclosed to exert important roles in human cancers, including gastric cancer (GC). CircRNA hsa_circ_0000144 was identified as an oncogene in GC development. The aim of our study was to explore the role of hsa_circ_0000144 in oxaliplatin (OXA) resistance of GC. Exp...
Gespeichert in:
| Veröffentlicht in: | OncoTargets and therapy 2021-01, Vol.14, p.2773-2787 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2787 |
|---|---|
| container_issue | |
| container_start_page | 2773 |
| container_title | OncoTargets and therapy |
| container_volume | 14 |
| creator | Gao, Haifeng Xu, Jiajia Qiao, Fen Xue, Liangjun |
| description | Circular RNAs (circRNAs) have been disclosed to exert important roles in human cancers, including gastric cancer (GC). CircRNA hsa_circ_0000144 was identified as an oncogene in GC development. The aim of our study was to explore the role of hsa_circ_0000144 in oxaliplatin (OXA) resistance of GC.
Expression levels of hsa_circ_0000144, microRNA-502-5p (miR-502-5p) and A disintegrin and metalloproteinase 9 (ADAM9) were examined by quantitative real-time PCR (RT-qPCR) or Western blot assay. The OXA resistance of GC cells was evaluated by Cell Counting Kit-8 (CCK-8) assay. Colony formation assay was performed to assess the colony formation capacity. Cell apoptosis was determined by flow cytometry and caspase 3 activity. And cell migration and invasion were detected by Transwell assay. Target association between miR-502-5p and hsa_circ_0000144 or ADAM9 was demonstrated by dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. Moreover, role of hsa_circ_0000144 in vivo was analyzed by xenograft tumor assay.
Hsa_circ_0000144 and ADAM9 were highly expressed, while miR-502-5p was downregulated in OXA-resistant GC tissues and cells. Depletion of hsa_circ_0000144 could inhibit OXA resistance, proliferation and metastasis in OXA-resistant GC cells, which was attenuated by miR-502-5p inhibition. Hsa_circ_0000144 sponged miR-502-5p to positively regulate ADAM9 expression. MiR-502-5p suppressed OXA resistance, proliferation and metastasis in OXA-resistant GC cells by targeting ADAM9. Hsa_circ_0000144 knockdown could hamper tumor growth in vivo.
Hsa_circ_0000144 exerted inhibitory effects on OXA resistance, proliferation and metastasis of OXA-resistant GC cells by regulating miR-502-5p/ADAM9 axis, at least in part. |
| doi_str_mv | 10.2147/OTT.S281238 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8068497</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2528202728</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-db921b31d6a26c6c0fb9e40d5608dbebed685e4a7258e2e520ac5ff3b5fb32b13</originalsourceid><addsrcrecordid>eNpdkd1LHDEUxUOp1I_2qe8l0BehjOZ7Mi_CsrYqWBZ0-xySzJ01MjszJjOi-M-bravY3pdcbn45nJuD0FdKjhgV5fFiuTy6Zpoyrj-gPUpLXaiKk4_v-l20n9ItIUppJj6hXc4rUgpG9tDTKQwtjKHvcN_gm2SND9EbkosKga-nYYiQEiS8eLBtGFo7hg5fQQpptJ2Hzaszm8YYPJ5vBhHPoW0Tdo-ZWk1_-RVeh6tCElbI4Xh2Ovtd4dlDSJ_RTmPbBF-25wH68-vncn5eXC7OLuazy8ILSceidhWjjtNaWaa88qRxFQhSS0V07cBBrbQEYUsmNTCQjFgvm4Y72TjOHOUH6ORFd5jcGmoP3Rhta4YY1jY-mt4G8-9NF27Mqr83migtqjILHG4FYn83QRrNOiSf17Qd9FMyTNKK57-mJKPf_0Nv-yl2eb1MMc0IK5nO1I8Xysc-pQjNmxlKzCZUk0M121Az_e29_zf2NUX-DBzAnI8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528202728</pqid></control><display><type>article</type><title>Depletion of hsa_circ_0000144 Suppresses Oxaliplatin Resistance of Gastric Cancer Cells by Regulating miR-502-5p/ADAM9 Axis</title><source>PubMed (Medline)</source><source>Taylor & Francis Open Access</source><source>DOVE Medical Press OA Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central Open Access</source><creator>Gao, Haifeng ; Xu, Jiajia ; Qiao, Fen ; Xue, Liangjun</creator><creatorcontrib>Gao, Haifeng ; Xu, Jiajia ; Qiao, Fen ; Xue, Liangjun</creatorcontrib><description>Circular RNAs (circRNAs) have been disclosed to exert important roles in human cancers, including gastric cancer (GC). CircRNA hsa_circ_0000144 was identified as an oncogene in GC development. The aim of our study was to explore the role of hsa_circ_0000144 in oxaliplatin (OXA) resistance of GC.
Expression levels of hsa_circ_0000144, microRNA-502-5p (miR-502-5p) and A disintegrin and metalloproteinase 9 (ADAM9) were examined by quantitative real-time PCR (RT-qPCR) or Western blot assay. The OXA resistance of GC cells was evaluated by Cell Counting Kit-8 (CCK-8) assay. Colony formation assay was performed to assess the colony formation capacity. Cell apoptosis was determined by flow cytometry and caspase 3 activity. And cell migration and invasion were detected by Transwell assay. Target association between miR-502-5p and hsa_circ_0000144 or ADAM9 was demonstrated by dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. Moreover, role of hsa_circ_0000144 in vivo was analyzed by xenograft tumor assay.
Hsa_circ_0000144 and ADAM9 were highly expressed, while miR-502-5p was downregulated in OXA-resistant GC tissues and cells. Depletion of hsa_circ_0000144 could inhibit OXA resistance, proliferation and metastasis in OXA-resistant GC cells, which was attenuated by miR-502-5p inhibition. Hsa_circ_0000144 sponged miR-502-5p to positively regulate ADAM9 expression. MiR-502-5p suppressed OXA resistance, proliferation and metastasis in OXA-resistant GC cells by targeting ADAM9. Hsa_circ_0000144 knockdown could hamper tumor growth in vivo.
Hsa_circ_0000144 exerted inhibitory effects on OXA resistance, proliferation and metastasis of OXA-resistant GC cells by regulating miR-502-5p/ADAM9 axis, at least in part.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S281238</identifier><identifier>PMID: 33907420</identifier><language>eng</language><publisher>New Zealand: Taylor & Francis Ltd</publisher><subject>ADAM protein ; Apoptosis ; Biomarkers ; Cancer therapies ; Caspase-3 ; Cell growth ; Cell migration ; Cell proliferation ; Cholecystokinin ; Colonies ; Drug resistance ; Flow cytometry ; Gastric cancer ; Immunoprecipitation ; Metastases ; MicroRNAs ; miRNA ; Original Research ; Oxaliplatin ; Xenografts</subject><ispartof>OncoTargets and therapy, 2021-01, Vol.14, p.2773-2787</ispartof><rights>2021 Gao et al.</rights><rights>2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Gao et al. 2021 Gao et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-db921b31d6a26c6c0fb9e40d5608dbebed685e4a7258e2e520ac5ff3b5fb32b13</citedby><cites>FETCH-LOGICAL-c451t-db921b31d6a26c6c0fb9e40d5608dbebed685e4a7258e2e520ac5ff3b5fb32b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068497/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068497/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3862,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33907420$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Haifeng</creatorcontrib><creatorcontrib>Xu, Jiajia</creatorcontrib><creatorcontrib>Qiao, Fen</creatorcontrib><creatorcontrib>Xue, Liangjun</creatorcontrib><title>Depletion of hsa_circ_0000144 Suppresses Oxaliplatin Resistance of Gastric Cancer Cells by Regulating miR-502-5p/ADAM9 Axis</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Circular RNAs (circRNAs) have been disclosed to exert important roles in human cancers, including gastric cancer (GC). CircRNA hsa_circ_0000144 was identified as an oncogene in GC development. The aim of our study was to explore the role of hsa_circ_0000144 in oxaliplatin (OXA) resistance of GC.
Expression levels of hsa_circ_0000144, microRNA-502-5p (miR-502-5p) and A disintegrin and metalloproteinase 9 (ADAM9) were examined by quantitative real-time PCR (RT-qPCR) or Western blot assay. The OXA resistance of GC cells was evaluated by Cell Counting Kit-8 (CCK-8) assay. Colony formation assay was performed to assess the colony formation capacity. Cell apoptosis was determined by flow cytometry and caspase 3 activity. And cell migration and invasion were detected by Transwell assay. Target association between miR-502-5p and hsa_circ_0000144 or ADAM9 was demonstrated by dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. Moreover, role of hsa_circ_0000144 in vivo was analyzed by xenograft tumor assay.
Hsa_circ_0000144 and ADAM9 were highly expressed, while miR-502-5p was downregulated in OXA-resistant GC tissues and cells. Depletion of hsa_circ_0000144 could inhibit OXA resistance, proliferation and metastasis in OXA-resistant GC cells, which was attenuated by miR-502-5p inhibition. Hsa_circ_0000144 sponged miR-502-5p to positively regulate ADAM9 expression. MiR-502-5p suppressed OXA resistance, proliferation and metastasis in OXA-resistant GC cells by targeting ADAM9. Hsa_circ_0000144 knockdown could hamper tumor growth in vivo.
Hsa_circ_0000144 exerted inhibitory effects on OXA resistance, proliferation and metastasis of OXA-resistant GC cells by regulating miR-502-5p/ADAM9 axis, at least in part.</description><subject>ADAM protein</subject><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>Caspase-3</subject><subject>Cell growth</subject><subject>Cell migration</subject><subject>Cell proliferation</subject><subject>Cholecystokinin</subject><subject>Colonies</subject><subject>Drug resistance</subject><subject>Flow cytometry</subject><subject>Gastric cancer</subject><subject>Immunoprecipitation</subject><subject>Metastases</subject><subject>MicroRNAs</subject><subject>miRNA</subject><subject>Original Research</subject><subject>Oxaliplatin</subject><subject>Xenografts</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkd1LHDEUxUOp1I_2qe8l0BehjOZ7Mi_CsrYqWBZ0-xySzJ01MjszJjOi-M-bravY3pdcbn45nJuD0FdKjhgV5fFiuTy6Zpoyrj-gPUpLXaiKk4_v-l20n9ItIUppJj6hXc4rUgpG9tDTKQwtjKHvcN_gm2SND9EbkosKga-nYYiQEiS8eLBtGFo7hg5fQQpptJ2Hzaszm8YYPJ5vBhHPoW0Tdo-ZWk1_-RVeh6tCElbI4Xh2Ovtd4dlDSJ_RTmPbBF-25wH68-vncn5eXC7OLuazy8ILSceidhWjjtNaWaa88qRxFQhSS0V07cBBrbQEYUsmNTCQjFgvm4Y72TjOHOUH6ORFd5jcGmoP3Rhta4YY1jY-mt4G8-9NF27Mqr83migtqjILHG4FYn83QRrNOiSf17Qd9FMyTNKK57-mJKPf_0Nv-yl2eb1MMc0IK5nO1I8Xysc-pQjNmxlKzCZUk0M121Az_e29_zf2NUX-DBzAnI8</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Gao, Haifeng</creator><creator>Xu, Jiajia</creator><creator>Qiao, Fen</creator><creator>Xue, Liangjun</creator><general>Taylor & Francis Ltd</general><general>Dove</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210101</creationdate><title>Depletion of hsa_circ_0000144 Suppresses Oxaliplatin Resistance of Gastric Cancer Cells by Regulating miR-502-5p/ADAM9 Axis</title><author>Gao, Haifeng ; Xu, Jiajia ; Qiao, Fen ; Xue, Liangjun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-db921b31d6a26c6c0fb9e40d5608dbebed685e4a7258e2e520ac5ff3b5fb32b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>ADAM protein</topic><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>Caspase-3</topic><topic>Cell growth</topic><topic>Cell migration</topic><topic>Cell proliferation</topic><topic>Cholecystokinin</topic><topic>Colonies</topic><topic>Drug resistance</topic><topic>Flow cytometry</topic><topic>Gastric cancer</topic><topic>Immunoprecipitation</topic><topic>Metastases</topic><topic>MicroRNAs</topic><topic>miRNA</topic><topic>Original Research</topic><topic>Oxaliplatin</topic><topic>Xenografts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gao, Haifeng</creatorcontrib><creatorcontrib>Xu, Jiajia</creatorcontrib><creatorcontrib>Qiao, Fen</creatorcontrib><creatorcontrib>Xue, Liangjun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Haifeng</au><au>Xu, Jiajia</au><au>Qiao, Fen</au><au>Xue, Liangjun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Depletion of hsa_circ_0000144 Suppresses Oxaliplatin Resistance of Gastric Cancer Cells by Regulating miR-502-5p/ADAM9 Axis</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>14</volume><spage>2773</spage><epage>2787</epage><pages>2773-2787</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Circular RNAs (circRNAs) have been disclosed to exert important roles in human cancers, including gastric cancer (GC). CircRNA hsa_circ_0000144 was identified as an oncogene in GC development. The aim of our study was to explore the role of hsa_circ_0000144 in oxaliplatin (OXA) resistance of GC.
Expression levels of hsa_circ_0000144, microRNA-502-5p (miR-502-5p) and A disintegrin and metalloproteinase 9 (ADAM9) were examined by quantitative real-time PCR (RT-qPCR) or Western blot assay. The OXA resistance of GC cells was evaluated by Cell Counting Kit-8 (CCK-8) assay. Colony formation assay was performed to assess the colony formation capacity. Cell apoptosis was determined by flow cytometry and caspase 3 activity. And cell migration and invasion were detected by Transwell assay. Target association between miR-502-5p and hsa_circ_0000144 or ADAM9 was demonstrated by dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. Moreover, role of hsa_circ_0000144 in vivo was analyzed by xenograft tumor assay.
Hsa_circ_0000144 and ADAM9 were highly expressed, while miR-502-5p was downregulated in OXA-resistant GC tissues and cells. Depletion of hsa_circ_0000144 could inhibit OXA resistance, proliferation and metastasis in OXA-resistant GC cells, which was attenuated by miR-502-5p inhibition. Hsa_circ_0000144 sponged miR-502-5p to positively regulate ADAM9 expression. MiR-502-5p suppressed OXA resistance, proliferation and metastasis in OXA-resistant GC cells by targeting ADAM9. Hsa_circ_0000144 knockdown could hamper tumor growth in vivo.
Hsa_circ_0000144 exerted inhibitory effects on OXA resistance, proliferation and metastasis of OXA-resistant GC cells by regulating miR-502-5p/ADAM9 axis, at least in part.</abstract><cop>New Zealand</cop><pub>Taylor & Francis Ltd</pub><pmid>33907420</pmid><doi>10.2147/OTT.S281238</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-6930 |
| ispartof | OncoTargets and therapy, 2021-01, Vol.14, p.2773-2787 |
| issn | 1178-6930 1178-6930 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8068497 |
| source | PubMed (Medline); Taylor & Francis Open Access; DOVE Medical Press OA Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central Open Access |
| subjects | ADAM protein Apoptosis Biomarkers Cancer therapies Caspase-3 Cell growth Cell migration Cell proliferation Cholecystokinin Colonies Drug resistance Flow cytometry Gastric cancer Immunoprecipitation Metastases MicroRNAs miRNA Original Research Oxaliplatin Xenografts |
| title | Depletion of hsa_circ_0000144 Suppresses Oxaliplatin Resistance of Gastric Cancer Cells by Regulating miR-502-5p/ADAM9 Axis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T10%3A22%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Depletion%20of%20hsa_circ_0000144%20Suppresses%20Oxaliplatin%20Resistance%20of%20Gastric%20Cancer%20Cells%20by%20Regulating%20miR-502-5p/ADAM9%20Axis&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Gao,%20Haifeng&rft.date=2021-01-01&rft.volume=14&rft.spage=2773&rft.epage=2787&rft.pages=2773-2787&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S281238&rft_dat=%3Cproquest_pubme%3E2528202728%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2528202728&rft_id=info:pmid/33907420&rfr_iscdi=true |